Cooley advised NeuExcell Therapeutics on the deal.NeuExcell Therapeutics, a neurodegenerative disease gene therapy company, announced its $15 million+ Series Pre-A+ financing round. Investors in the round included…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
